InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2025-10-31 00:00:00 ET · period of report 2025-10-29 · accession 0001189014-25-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-10-31 2025-10-29 REGN POON CHRISTINE A Dir S - Sale+OE $654.27 -6,500 3,552 -65% -$4.25M
DM 2025-10-31 2025-10-29+ REGN POON CHRISTINE A Dir M - OptEx $520.01 +9,212 8,852 New +$4.79M
DM 2025-10-31 2025-10-29+ REGN POON CHRISTINE A Dir M - OptEx $0.00 -9,212 2,712 -77% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-10-29 S D 2,735 $653.50 5,467 D — — (F2) Represents volume-weighted average price of sales of 2,735 shares of Company stock on October 29, 2025 at prices ranging from $653.05 to $653.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
2 Common Common Stock 2025-10-29 S D 650 $652.68 8,202 D — — (F1) Represents volume-weighted average price of sales of 650 shares of Company stock on October 29, 2025 at prices ranging from $652.31 to $652.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
3 Common Common Stock 2025-10-29 S D 388 $657.29 2,352 D — — (F6) Represents volume-weighted average price of sales of 388 shares of Company stock on October 29, 2025 at prices ranging from $657.02 to $657.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
4 Common Common Stock 2025-10-30 M A 2,712 $520.01 5,064 D — —
5 Common Common Stock 2025-10-29 S D 712 $656.50 2,740 D — — (F5) Represents volume-weighted average price of sales of 712 shares of Company stock on October 29, 2025 at prices ranging from $656.33 to $656.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
6 Common Common Stock 2025-10-29 M A 6,500 $520.01 8,852 D — —
7 Common Common Stock 2025-10-29 S D 100 $655.10 3,452 D — — (F4) Represents volume-weighted average price of sales of 100 shares of Company stock on October 29, 2025 at prices ranging from $655.02 to $655.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
8 Common Common Stock 2025-10-29 S D 1,915 $654.42 3,552 D — — (F3) Represents volume-weighted average price of sales of 1,915 shares of Company stock on October 29, 2025 at prices ranging from $654.01 to $654.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
9 Derivative Non-Qualified Stock Option (right to buy) 2025-10-30 M D 2,712 $0.00 0 D $520.01 · — to 2026-01-04 2,712 Common Stock (F7) The stock option vested in three equal annual installments, commencing one year after the date of grant.
10 Derivative Non-Qualified Stock Option (right to buy) 2025-10-29 M D 6,500 $0.00 2,712 D $520.01 · — to 2026-01-04 6,500 Common Stock (F7) The stock option vested in three equal annual installments, commencing one year after the date of grant.